RASP (Actavia Life Sciences) ROE %: 0.00% (As of Mar. 2024)


What is Actavia Life Sciences ROE %?

Actavia Life Sciences RASP -87.50% ROE % is 0.00% as of Mar. 2024.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Actavia Life Sciences's annualized net income for the quarter that ended in Mar. 2024 was $-0.38 Mil. Actavia Life Sciences's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $-2.14 Mil. Therefore, Actavia Life Sciences's annualized ROE % for the quarter that ended in Mar. 2024 was N/A%.

The historical rank and industry rank for Actavia Life Sciences's ROE % or its related term are showing as below:

RASP's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.18
* Ranked among companies with meaningful ROE % only.

Actavia Life Sciences  (OTCPK:RASP) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-0.384/-2.143
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.384 / 0)*(0 / 0.0375)*(0.0375 / -2.143)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-0.384/-2.143
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.384 / -0.384) * (-0.384 / -0.284) * (-0.284 / 0) * (0 / 0.0375) * (0.0375 / -2.143)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.3521 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

Actavia Life Sciences ROE % Related Terms

Actavia Life Sciences ROE % Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences ROE % Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.17 0.00 0.00 0.00 0.00

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RASP vs BWV, FNCH, CWBR: ROE % Comparison

For the Biotechnology subindustry, Actavia Life Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actavia Life Sciences ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's ROE % distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's ROE % falls into.


Actavia Life Sciences ROE % Calculation

Actavia Life Sciences's annualized ROE % for the fiscal year that ended in Sep. 2023 is calculated as

ROE %=Net Income (A: Sep. 2023 )/( (Total Stockholders Equity (A: Sep. 2022 )+Total Stockholders Equity (A: Sep. 2023 ))/ count )
=-4.443/( (-1.689+-1.956)/ 2 )
=-4.443/-1.8225
=N/A %

Actavia Life Sciences's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-0.384/( (-2.104+-2.182)/ 2 )
=-0.384/-2.143
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Actavia Life Sciences (RASP) has a ROE % of 0.00% as of Mar. 2024. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' ROE % too high?
Actavia Life Sciences' current ROE % is 0.00%.
How does Actavia Life Sciences' ROE % compare to BWV and FNCH?
Actavia Life Sciences' ROE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Actavia Life Sciences and its competitors. Actavia Life Sciences's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current ROE % of 0.00%. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current ROE % is 0.00% as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.